The Summary
This retrospective cohort study analyzed US health records of 2,396 adults without diabetes taking either tirzepatide or semaglutide for six months. Researchers found tirzepatide led to greater average reductions (-11.15% versus -8.83%) compared to semaglutide. Patients on tirzepatide were also more likely to hit major reduction targets and showed better improvements in blood pressure and HbA1c. Notably, this advantage appeared even though a larger percentage of semaglutide users were taking higher maintenance doses than the tirzepatide users.
Why this is interesting
While clinical trials suggested tirzepatide might edge out semaglutide, real-world evidence was needed to confirm it. This study shows that everyday patients using tirzepatide achieve noticeably better results and cardiovascular improvements in just six months compared to semaglutide users. For anyone considering these medications, it provides clearer expectations about which drug might offer faster or more significant results. Discussing these nuances with your doctor can help you choose the best medication for your personal health goals.